Genix Pharmaceuticals Corporation
Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with focus on nutraceuticals and pharmaceuticals in Canada. The company develops Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Renochlor, a dietary supplement to support kidney health; and Sucanon, a herbal health supplement to manage blood… Read more
Market Cap & Net Worth: Genix Pharmaceuticals Corporation (GENPF)
Genix Pharmaceuticals Corporation (OTCQB:GENPF) has a market capitalization of $2.37 Million ($2.37 Million) as of March 19, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #35363 globally and #11524 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Genix Pharmaceuticals Corporation's stock price $0.04 by its total outstanding shares 59224100 (59.22 Million).
Genix Pharmaceuticals Corporation Market Cap History: 2021 to 2025
Genix Pharmaceuticals Corporation's market capitalization history from 2021 to 2025. Data shows change from $5.04 Million to $2.37 Million (-29.75% CAGR).
Genix Pharmaceuticals Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Genix Pharmaceuticals Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
584.78x
Genix Pharmaceuticals Corporation's market cap is 584.78 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $817.29K | $12.35K | -$4.40 Million | 66.19x | N/A |
| 2024 | $2.37 Million | $4.05K | -$73.20K | 584.78x | N/A |
Competitor Companies of GENPF by Market Capitalization
Companies near Genix Pharmaceuticals Corporation in the global market cap rankings as of March 19, 2026.
Key companies related to Genix Pharmaceuticals Corporation by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Genix Pharmaceuticals Corporation Historical Marketcap From 2021 to 2025
Between 2021 and today, Genix Pharmaceuticals Corporation's market cap moved from $5.04 Million to $ 2.37 Million, with a yearly change of -29.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $2.37 Million | 0.00% |
| 2024 | $2.37 Million | +189.86% |
| 2023 | $817.29K | -79.09% |
| 2022 | $3.91 Million | -22.44% |
| 2021 | $5.04 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Genix Pharmaceuticals Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.37 Million USD |
| MoneyControl | $2.37 Million USD |
| MarketWatch | $2.37 Million USD |
| marketcap.company | $2.37 Million USD |
| Reuters | $2.37 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.